Synthetic THC (dronabinol) shows promise in reducing agitation in Alzheimer's patients in a 75-outpatient study.

Research presented at the International Psychogeriatrics Association meeting in Buenos Aires indicates that synthetic THC (dronabinol) may reduce agitation in Alzheimer's patients. In a study involving 75 outpatients, those taking 5 mg of dronabinol twice daily showed significant improvement in agitation symptoms compared to a placebo group. The drug was well-tolerated, offering hope for the 7 million Americans with Alzheimer's, though further studies are needed for conclusive results.

September 30, 2024
7 Articles